Table III.
Association between inhibition rates of chemotherapy agents and clinical characteristics.
| Inhibition rates (%) of chemotherapy agents (mean and 95% CI)a | ||||||
|---|---|---|---|---|---|---|
| Clinical values | Cisplatin | Docetaxel | Gemcitabine | Etoposide | Fluorouracil | Irinotecan |
| Sex | ||||||
| Male | 39.1 (31.2–46.9) | 21.3 (15.9–26.7) | 18.4 (13.7–23.0) | 20.1 (14.9–25.1) | 17.5 (13.9–21.2) | 20.5 (14.7–26.3) |
| Female | 45.9 (36.3–55.5) | 14.9 (9.6–20.3) | 28.7 (19.3–38.0) | 19.7 (12.9–26.5) | 22.9 (14.6–31.3) | 22.4 (14.2–30.5) |
| Age | ||||||
| ≤62 | 42.0 (34.5–49.5) | 21.3 (16.5–26.2) | 21.5 (15.5–27.4) | 22.3 (16.6–28.1) | 21.4 (15.9–26.8) | 25.1 (19.0–31.2) |
| >62 | 41.1 (30.8–51.4) | 16.1 (9.4–22.7) | 23.0 (15.4–30.6) | 16.9 (11.6–22.3) | 17.3 (11.9–22.6) | 16.4 (9.6–23.2) |
| Tumor site | ||||||
| Upper | 39.0 (12.3–65.8) | 33.8 (12.4–55.3) | 30.4 (0.0–61.2) | 26.8 (12.1–41.4) | 29.1 (14.8–43.3) | 22.9 (5.1–50.9) |
| Middle | 43.9 (35.8–52.2) | 15.4 (11.2–19.5) | 21.4 (16.7–26.1) | 18.9 (13.6–24.3) | 19.5 (14.2–24.7) | 20.0 (15.0–25.0) |
| Lower | 37.8 (27.0–48.7) | 21.0 (13.1–28.9) | 20.9 (10.6–31.3) | 19.5 (12.0–29.9) | 16.4 (10.4–22.5) | 23.0 (12.5–33.4) |
| Histological grade | ||||||
| 1 | 39.7 (20.1–59.3) | 22.6 (14.6–30.7) | 21.7 (8.9–34.5) | 27.4 (15.4–39.4) | 22.2 (11.1–33.4) | 26.2 (10.8–41.5) |
| 2 | 42.1 (35.9–48.3) | 18.1 (13.5–22.6) | 22.3 (17.2–27.3) | 18.0 (14.0–21.9) | 18.8 (14.8–22.8) | 19.9 (15.4–23.5) |
| Stage | ||||||
| II | 44.4 (35.9–52.9) | 17.2 (11.9–22.4) | 24.2 (16.7–31.6) | 21.4 (15.8–26.9) | 22.0 (16.1–27.9) | 21.5 (13.6–29.4) |
| III | 38.1 (29.4–46.8) | 21.2 (15.0–27.4) | 19.7 (14.8–24.6) | 18.1 (12.3–23.9) | 16.4 (12.3–20.6) | 20.9 (17.0–24.7) |
a
All P>0.05. CI, confidence interval.